[
  {
    "ts": null,
    "headline": "SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies",
    "summary": "SOUTH SAN FRANCISCO, Calif., January 08, 2026--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15.",
    "url": "https://finnhub.io/api/news?id=5aa1407c23dd2f059ed8d1ad28364876d555cf2a033fd95f8217467fdd28ee11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767890280,
      "headline": "SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies",
      "id": 138038352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., January 08, 2026--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15.",
      "url": "https://finnhub.io/api/news?id=5aa1407c23dd2f059ed8d1ad28364876d555cf2a033fd95f8217467fdd28ee11"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Replaces Proxy Advisers With AI",
    "summary": "Proxy firms pushed out of process",
    "url": "https://finnhub.io/api/news?id=d42bcca018479837912b0a167d927c6eede9acae33b4baea1dd354f1be77a9ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767889186,
      "headline": "JPMorgan Replaces Proxy Advisers With AI",
      "id": 138038353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Proxy firms pushed out of process",
      "url": "https://finnhub.io/api/news?id=d42bcca018479837912b0a167d927c6eede9acae33b4baea1dd354f1be77a9ba"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan takes over Apple card, Paramount reaffirms WBD bid",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Goldman Sachs (GS) reaching a deal to sell its Apple credit card (AAPL) to JPMorgan Chase (JPM), Paramount Skydance (PSKY) reaffirming its offer to acquire Warner Bros. Discovery (WBD), and CrowdStrike's (CRWD) $740 million purchase of SGNL. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=43a5fd78d61643854c1e7f2f664f0746410f911d12ecb9232a177695304054a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767888109,
      "headline": "JPMorgan takes over Apple card, Paramount reaffirms WBD bid",
      "id": 138036452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Goldman Sachs (GS) reaching a deal to sell its Apple credit card (AAPL) to JPMorgan Chase (JPM), Paramount Skydance (PSKY) reaffirming its offer to acquire Warner Bros. Discovery (WBD), and CrowdStrike's (CRWD) $740 million purchase of SGNL. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=43a5fd78d61643854c1e7f2f664f0746410f911d12ecb9232a177695304054a8"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Flags Crypto Sell-off Bottom as ETF Flows Turn Two-Way",
    "summary": "JPMorgan analysts pointed to a stabilizing flow pressure across spot crypto ETFs in early January, after two months of late 2025 de-risking that leaned heavily on ETF redemptions rather than a liquidity freeze. Bitcoin is currently trading at $90,428 (-2.50%) in the latest print, while Ethereum is trading at $3,100 ...",
    "url": "https://finnhub.io/api/news?id=fcc8b5b5af67fc2357a69a996dba907b25776f023e2522986401c7207290d4a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767888103,
      "headline": "JPMorgan Flags Crypto Sell-off Bottom as ETF Flows Turn Two-Way",
      "id": 138038354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan analysts pointed to a stabilizing flow pressure across spot crypto ETFs in early January, after two months of late 2025 de-risking that leaned heavily on ETF redemptions rather than a liquidity freeze. Bitcoin is currently trading at $90,428 (-2.50%) in the latest print, while Ethereum is trading at $3,100 ...",
      "url": "https://finnhub.io/api/news?id=fcc8b5b5af67fc2357a69a996dba907b25776f023e2522986401c7207290d4a1"
    }
  },
  {
    "ts": null,
    "headline": "ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (\"ALX Oncology\"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 1",
    "url": "https://finnhub.io/api/news?id=6eb3b81768a26cec9f3a177e9c6251a1156d3a19844cd3bd290abdfa5764f3c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767888000,
      "headline": "ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138036566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (\"ALX Oncology\"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 1",
      "url": "https://finnhub.io/api/news?id=6eb3b81768a26cec9f3a177e9c6251a1156d3a19844cd3bd290abdfa5764f3c9"
    }
  },
  {
    "ts": null,
    "headline": "How The Crédit Agricole (ENXTPA:ACA) Story Is Shifting After JPMorgan’s Target Cut",
    "summary": "Crédit Agricole’s stock story has been refreshed after a large bank moved its price target to €16.50 from €17.00, a tweak that still points to some potential upside in the eyes of more optimistic analysts. At the same time, your own model fair value sits higher at €18.77 per share, built on unchanged assumptions for discount rate, revenue growth, net profit margin, and future P/E. This frames this target cut more as a fine tune than a reset. Stay with this article to see how you can keep on...",
    "url": "https://finnhub.io/api/news?id=e7765f46ad286be46dca9f0cb6343194119ac2eaf557f5cfdfe247e1798edf1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767885307,
      "headline": "How The Crédit Agricole (ENXTPA:ACA) Story Is Shifting After JPMorgan’s Target Cut",
      "id": 138036567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Crédit Agricole’s stock story has been refreshed after a large bank moved its price target to €16.50 from €17.00, a tweak that still points to some potential upside in the eyes of more optimistic analysts. At the same time, your own model fair value sits higher at €18.77 per share, built on unchanged assumptions for discount rate, revenue growth, net profit margin, and future P/E. This frames this target cut more as a fine tune than a reset. Stay with this article to see how you can keep on...",
      "url": "https://finnhub.io/api/news?id=e7765f46ad286be46dca9f0cb6343194119ac2eaf557f5cfdfe247e1798edf1c"
    }
  },
  {
    "ts": null,
    "headline": "Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "SOUTH SAN FRANCISCO, Calif., January 08, 2026--Encoded Therapeutics Inc. (\"Encoded\"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today provided an update on the significant progress made during 2025 with its Dravet syndrome candidate, ETX101, including an overview of the positive interim Phase 1/2 clinical results announced last month, establishment of GMP manufacturing capabilities to support its pipeline of gene therapies, and progres",
    "url": "https://finnhub.io/api/news?id=74160e91d9716aedcffa6bf85c562c02008acba7a2bf84cfa0847dab1e7ae959",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767884400,
      "headline": "Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138036569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., January 08, 2026--Encoded Therapeutics Inc. (\"Encoded\"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today provided an update on the significant progress made during 2025 with its Dravet syndrome candidate, ETX101, including an overview of the positive interim Phase 1/2 clinical results announced last month, establishment of GMP manufacturing capabilities to support its pipeline of gene therapies, and progres",
      "url": "https://finnhub.io/api/news?id=74160e91d9716aedcffa6bf85c562c02008acba7a2bf84cfa0847dab1e7ae959"
    }
  },
  {
    "ts": null,
    "headline": "Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise",
    "summary": "The life sciences industry is buzzing about AI's potential to transform drug discovery. But at this year's J.P. Morgan Healthcare Conference, the real conversation isn't about finding the perfect algorithm -- it's about fixing the ecosystem that makes AI work.",
    "url": "https://finnhub.io/api/news?id=367363301625416c1a5b4ac6bab87e403720f2a010293a7fe74d2f419f4b2160",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767884400,
      "headline": "Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise",
      "id": 138036568,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The life sciences industry is buzzing about AI's potential to transform drug discovery. But at this year's J.P. Morgan Healthcare Conference, the real conversation isn't about finding the perfect algorithm -- it's about fixing the ecosystem that makes AI work.",
      "url": "https://finnhub.io/api/news?id=367363301625416c1a5b4ac6bab87e403720f2a010293a7fe74d2f419f4b2160"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Downgrades JPMorgan and Bank of America Ahead of Earnings",
    "summary": "The firm cites limited upside after a strong 2025 rally as major US banks prepare to report results next week.",
    "url": "https://finnhub.io/api/news?id=311fc00970a3782d4fe8a9652536113e470b3b387c35ddf09f8917cf72b4a99e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767883817,
      "headline": "Wolfe Research Downgrades JPMorgan and Bank of America Ahead of Earnings",
      "id": 138036570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The firm cites limited upside after a strong 2025 rally as major US banks prepare to report results next week.",
      "url": "https://finnhub.io/api/news?id=311fc00970a3782d4fe8a9652536113e470b3b387c35ddf09f8917cf72b4a99e"
    }
  },
  {
    "ts": null,
    "headline": "The Apple Card headache for Goldman Sachs is almost over",
    "summary": "Goldman's long push into the consumer business finally nears its end.",
    "url": "https://finnhub.io/api/news?id=ee71e80452b73c3eef62a81fb67c41b51a431fa876e6f125476e35b4303bdbf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767882823,
      "headline": "The Apple Card headache for Goldman Sachs is almost over",
      "id": 138038355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Goldman's long push into the consumer business finally nears its end.",
      "url": "https://finnhub.io/api/news?id=ee71e80452b73c3eef62a81fb67c41b51a431fa876e6f125476e35b4303bdbf0"
    }
  },
  {
    "ts": null,
    "headline": "After clinching Apple Card sale to JPMorgan, Goldman Sachs nears the end of its years-long consumer headache",
    "summary": "Goldman's long push into the consumer business finally nears its end.",
    "url": "https://finnhub.io/api/news?id=587033989ad892afeb17ce4632daa2f36907572c72493de395d8701df22b7c73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767882823,
      "headline": "After clinching Apple Card sale to JPMorgan, Goldman Sachs nears the end of its years-long consumer headache",
      "id": 138036459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Goldman's long push into the consumer business finally nears its end.",
      "url": "https://finnhub.io/api/news?id=587033989ad892afeb17ce4632daa2f36907572c72493de395d8701df22b7c73"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: JPMorgan To Take Over Apple Card From Goldman Sachs",
    "summary": "JPMorgan Chase (JPM) has struck a deal to acquire the Apple (AAPL) credit-card program from Goldman Sachs (GS), further cementing Chaseâs already dominant position in consumer credit.",
    "url": "https://finnhub.io/api/news?id=59d7106f9a272242a34104ab8494bfd00a366af0ac0f6265fc0f9fa3799f9745",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881790,
      "headline": "Wall Street Lunch: JPMorgan To Take Over Apple Card From Goldman Sachs",
      "id": 138039381,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1053526672/image_1053526672.jpg?io=getty-c-w1536",
      "related": "JPM",
      "source": "SeekingAlpha",
      "summary": "JPMorgan Chase (JPM) has struck a deal to acquire the Apple (AAPL) credit-card program from Goldman Sachs (GS), further cementing Chaseâs already dominant position in consumer credit.",
      "url": "https://finnhub.io/api/news?id=59d7106f9a272242a34104ab8494bfd00a366af0ac0f6265fc0f9fa3799f9745"
    }
  },
  {
    "ts": null,
    "headline": "Exploring Analyst Estimates for JPMorgan Chase & Co. (JPM) Q4 Earnings, Beyond Revenue and EPS",
    "summary": "Evaluate the expected performance of JPMorgan Chase & Co. (JPM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finnhub.io/api/news?id=b2f230bfac361518c55c6e228eec62824ab1cb887827399299aa68fec811eac8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881702,
      "headline": "Exploring Analyst Estimates for JPMorgan Chase & Co. (JPM) Q4 Earnings, Beyond Revenue and EPS",
      "id": 138036572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Evaluate the expected performance of JPMorgan Chase & Co. (JPM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
      "url": "https://finnhub.io/api/news?id=b2f230bfac361518c55c6e228eec62824ab1cb887827399299aa68fec811eac8"
    }
  },
  {
    "ts": null,
    "headline": "Apple Card switches hands but no immediate changes for users",
    "summary": "The Apple Card, known for its intuitive features and other perks for consumers, will now be issued by JPMorgan but Apple says nothing will change for users.  The handover to JP Morgan brings together companies that play an increasingly large role in the way people pay for everything from utility bills to socks using phones, tablets or watches.  Apple said that features including 3% cash back on purchases and high-yield savings account affiliated with the card, will remain.",
    "url": "https://finnhub.io/api/news?id=4747270844be48ad3bbf191242ce27adecbd8437028cda466671752b1bd37e2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881348,
      "headline": "Apple Card switches hands but no immediate changes for users",
      "id": 138036466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The Apple Card, known for its intuitive features and other perks for consumers, will now be issued by JPMorgan but Apple says nothing will change for users.  The handover to JP Morgan brings together companies that play an increasingly large role in the way people pay for everything from utility bills to socks using phones, tablets or watches.  Apple said that features including 3% cash back on purchases and high-yield savings account affiliated with the card, will remain.",
      "url": "https://finnhub.io/api/news?id=4747270844be48ad3bbf191242ce27adecbd8437028cda466671752b1bd37e2d"
    }
  },
  {
    "ts": null,
    "headline": "Immorta Bio Doubles Mouse Lifespan Using Combination Senolytic and Regenerative Therapy in Validated Aging Models",
    "summary": "Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced new data demonstrating that its combination therapy of SenoVax™, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its breakthrough StemCellRevivify™ platform, doubled lifespan and significantly extended healthspan in validated murine aging models.",
    "url": "https://finnhub.io/api/news?id=e37cbbee95bc4a001447e8d28cf3655fc0895b1bf3b3255b19ed56659c96995e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767878700,
      "headline": "Immorta Bio Doubles Mouse Lifespan Using Combination Senolytic and Regenerative Therapy in Validated Aging Models",
      "id": 138036574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced new data demonstrating that its combination therapy of SenoVax™, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its breakthrough StemCellRevivify™ platform, doubled lifespan and significantly extended healthspan in validated murine aging models.",
      "url": "https://finnhub.io/api/news?id=e37cbbee95bc4a001447e8d28cf3655fc0895b1bf3b3255b19ed56659c96995e"
    }
  },
  {
    "ts": null,
    "headline": "32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics",
    "summary": "NORTH CHICAGO, Ill., January 08, 2026--32 Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.",
    "url": "https://finnhub.io/api/news?id=20d90915745d60e915659847a0a34e7144a039de734d54ac8af6ba1adbec929e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767878100,
      "headline": "32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics",
      "id": 138036575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "NORTH CHICAGO, Ill., January 08, 2026--32 Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.",
      "url": "https://finnhub.io/api/news?id=20d90915745d60e915659847a0a34e7144a039de734d54ac8af6ba1adbec929e"
    }
  },
  {
    "ts": null,
    "headline": "Flare Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that Doug Manion, M.D., FRCP (C), Chief Executive Officer and Board Member, will present a company overview at the upcoming 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 8:00 a.m. PT in San Francisco, CA. About Flare T",
    "url": "https://finnhub.io/api/news?id=fc1831e0a414a39cb4172372000afcb7b624878d8c34de9a59f513511f942af5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877740,
      "headline": "Flare Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138036576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that Doug Manion, M.D., FRCP (C), Chief Executive Officer and Board Member, will present a company overview at the upcoming 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 8:00 a.m. PT in San Francisco, CA. About Flare T",
      "url": "https://finnhub.io/api/news?id=fc1831e0a414a39cb4172372000afcb7b624878d8c34de9a59f513511f942af5"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan cuts ties with proxy advisers, to replace with in-house AI, WSJ reports",
    "summary": "JPMorgan (JPM) Chase’s asset-management unit, among the world’s largest investment firms with more than $7 trillion in client assets, is cutting all ties with proxy-advisory firms effective immediately and will start using an internal artificial-intelligence-powered platform it is calling Proxy IQ to assist on U.S. company votes this coming proxy season, according to a memo seen by The Wall Street Journal.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for",
    "url": "https://finnhub.io/api/news?id=b599cdfd0c88ea80400e20771ad5a64287548c91bb29d7f8f205dfe377b4d94d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877267,
      "headline": "JPMorgan cuts ties with proxy advisers, to replace with in-house AI, WSJ reports",
      "id": 138036577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan (JPM) Chase’s asset-management unit, among the world’s largest investment firms with more than $7 trillion in client assets, is cutting all ties with proxy-advisory firms effective immediately and will start using an internal artificial-intelligence-powered platform it is calling Proxy IQ to assist on U.S. company votes this coming proxy season, according to a memo seen by The Wall Street Journal.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for",
      "url": "https://finnhub.io/api/news?id=b599cdfd0c88ea80400e20771ad5a64287548c91bb29d7f8f205dfe377b4d94d"
    }
  },
  {
    "ts": null,
    "headline": "Avenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "SCHAUMBURG, Ill., January 08, 2026--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today provided an update on recent business highlights and financial performance for 2025 and strategic priorities for 2026 ahead of the Company’s participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 in San Francisco, CA.",
    "url": "https://finnhub.io/api/news?id=a859c1384861babfb957868362cd7d6db82751785d46cd13b299930c0fa6aa59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877200,
      "headline": "Avenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138036578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SCHAUMBURG, Ill., January 08, 2026--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today provided an update on recent business highlights and financial performance for 2025 and strategic priorities for 2026 ahead of the Company’s participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 in San Francisco, CA.",
      "url": "https://finnhub.io/api/news?id=a859c1384861babfb957868362cd7d6db82751785d46cd13b299930c0fa6aa59"
    }
  },
  {
    "ts": null,
    "headline": "JEF Stock Falls 3.3% Despite Y/Y Increase in Q4 Earnings & Revenues",
    "summary": "Jefferies' shares slide 3.3% despite beating earnings and revenue estimates, as higher expenses weigh on fiscal Q4 results.",
    "url": "https://finnhub.io/api/news?id=f53973a2b319dd1dd09230f935519e337143771369bc85326b4142e28b02d27f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767876420,
      "headline": "JEF Stock Falls 3.3% Despite Y/Y Increase in Q4 Earnings & Revenues",
      "id": 138036579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Jefferies' shares slide 3.3% despite beating earnings and revenue estimates, as higher expenses weigh on fiscal Q4 results.",
      "url": "https://finnhub.io/api/news?id=f53973a2b319dd1dd09230f935519e337143771369bc85326b4142e28b02d27f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Calls JPMorgan “Outrageously Cheap Versus the Rest of the Market”",
    "summary": "JPMorgan Chase & Co. (NYSE:JPM) is one of the stocks Jim Cramer offered insights on. Cramer highlighted it as one of the stocks to buy more during a pullback. He stated: “Look, I think this kind of trading is really ill- advised. Long-term, I believe it’s going to give you suboptimal returns. It’s very rare […]",
    "url": "https://finnhub.io/api/news?id=19d79d2fbdbdcab46f5e53892a45ba82c8911d18f4d4fb76318c8bf01b77d1ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767876306,
      "headline": "Jim Cramer Calls JPMorgan “Outrageously Cheap Versus the Rest of the Market”",
      "id": 138036580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan Chase & Co. (NYSE:JPM) is one of the stocks Jim Cramer offered insights on. Cramer highlighted it as one of the stocks to buy more during a pullback. He stated: “Look, I think this kind of trading is really ill- advised. Long-term, I believe it’s going to give you suboptimal returns. It’s very rare […]",
      "url": "https://finnhub.io/api/news?id=19d79d2fbdbdcab46f5e53892a45ba82c8911d18f4d4fb76318c8bf01b77d1ab"
    }
  },
  {
    "ts": null,
    "headline": "Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the com",
    "url": "https://finnhub.io/api/news?id=2caba6de85375ec50b6f36d2eec8adcd6ca29102f4444e63e7ea020d289cd72f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767875400,
      "headline": "Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138036581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the com",
      "url": "https://finnhub.io/api/news?id=2caba6de85375ec50b6f36d2eec8adcd6ca29102f4444e63e7ea020d289cd72f"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Developments Are Shaping The NatWest Group LSE NWG Investment Story",
    "summary": "NatWest Group’s latest valuation update keeps fair value anchored at £6.63 while making only small tweaks to the inputs behind that number, including a slightly lower discount rate and unchanged revenue growth assumptions at around 6.28%. Together with full year 2025 guidance, recent deal discussions and a completed share buyback, these moves indicate that analysts are refining their models rather than rewriting the story. Stay with this article to see how you can track these kinds of...",
    "url": "https://finnhub.io/api/news?id=b24c85c7929ba5413023352f8b0469479a3a21dda46a96c7b2a2b9129eecfaa6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767874404,
      "headline": "How Recent Developments Are Shaping The NatWest Group LSE NWG Investment Story",
      "id": 138036582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "NatWest Group’s latest valuation update keeps fair value anchored at £6.63 while making only small tweaks to the inputs behind that number, including a slightly lower discount rate and unchanged revenue growth assumptions at around 6.28%. Together with full year 2025 guidance, recent deal discussions and a completed share buyback, these moves indicate that analysts are refining their models rather than rewriting the story. Stay with this article to see how you can track these kinds of...",
      "url": "https://finnhub.io/api/news?id=b24c85c7929ba5413023352f8b0469479a3a21dda46a96c7b2a2b9129eecfaa6"
    }
  },
  {
    "ts": null,
    "headline": "Apple Card Taken Over by JPMorgan. Why Goldman Has Exited the Credit Play.",
    "summary": "The deal ends a failed experiment in consumer lending for Goldman Sachs, which launched a card with Apple in 2019.",
    "url": "https://finnhub.io/api/news?id=5915e0e3f26b12171c6795ee3cd0f9201b72d51ac546912571ab6875b5bd4bbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767874380,
      "headline": "Apple Card Taken Over by JPMorgan. Why Goldman Has Exited the Credit Play.",
      "id": 138036583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The deal ends a failed experiment in consumer lending for Goldman Sachs, which launched a card with Apple in 2019.",
      "url": "https://finnhub.io/api/news?id=5915e0e3f26b12171c6795ee3cd0f9201b72d51ac546912571ab6875b5bd4bbf"
    }
  },
  {
    "ts": null,
    "headline": "What Could Be Changing The EssilorLuxottica (ENXTPA:EL) Story As Analyst Targets Rise",
    "summary": "The latest analyst revisions on EssilorLuxottica Société anonyme have nudged the consensus price target from €318.65 to €324.65, a modest shift that still reflects a tightly defined view of fair value. This update comes as analysts fine tune their models around growth expectations and risk assumptions, leading to small but meaningful changes in how they frame the stock’s potential. Stay tuned to see how you can keep on top of these evolving targets so you are not caught off guard as the...",
    "url": "https://finnhub.io/api/news?id=4e1af5b59afe2a3c4d6961ffbf6e73373b725fa3aac011f0278853cf3a02fc54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767874349,
      "headline": "What Could Be Changing The EssilorLuxottica (ENXTPA:EL) Story As Analyst Targets Rise",
      "id": 138036584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The latest analyst revisions on EssilorLuxottica Société anonyme have nudged the consensus price target from €318.65 to €324.65, a modest shift that still reflects a tightly defined view of fair value. This update comes as analysts fine tune their models around growth expectations and risk assumptions, leading to small but meaningful changes in how they frame the stock’s potential. Stay tuned to see how you can keep on top of these evolving targets so you are not caught off guard as the...",
      "url": "https://finnhub.io/api/news?id=4e1af5b59afe2a3c4d6961ffbf6e73373b725fa3aac011f0278853cf3a02fc54"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan abandons proxy advisers and turns to AI",
    "summary": "The decision applies immediately and comes as regulatory scrutiny increases around the proxy advisory sector.",
    "url": "https://finnhub.io/api/news?id=8c6c3455085a434d7697b43754dbb0e39e01aae79fb2e74dfc85c2ad55cc49f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767873741,
      "headline": "JPMorgan abandons proxy advisers and turns to AI",
      "id": 138034973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The decision applies immediately and comes as regulatory scrutiny increases around the proxy advisory sector.",
      "url": "https://finnhub.io/api/news?id=8c6c3455085a434d7697b43754dbb0e39e01aae79fb2e74dfc85c2ad55cc49f9"
    }
  },
  {
    "ts": null,
    "headline": "Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWI",
    "url": "https://finnhub.io/api/news?id=3cc3891f11e85a9a1ade5620f1b2a0411223a34dcb02606d43e144ec3217326c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767873600,
      "headline": "Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138034974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWI",
      "url": "https://finnhub.io/api/news?id=3cc3891f11e85a9a1ade5620f1b2a0411223a34dcb02606d43e144ec3217326c"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan to take over Apple credit card from Goldman Sachs",
    "summary": "The bank plans to record a $2.2bn provision for credit losses tied to the deal when it reports fourth-quarter 2025 earnings next week.",
    "url": "https://finnhub.io/api/news?id=11e67df50c584cc7e3ec4fd4819a69fbffdf910dbea17c95b1e616e201f132f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767873258,
      "headline": "JPMorgan to take over Apple credit card from Goldman Sachs",
      "id": 138034900,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The bank plans to record a $2.2bn provision for credit losses tied to the deal when it reports fourth-quarter 2025 earnings next week.",
      "url": "https://finnhub.io/api/news?id=11e67df50c584cc7e3ec4fd4819a69fbffdf910dbea17c95b1e616e201f132f1"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan outlines ten strategic themes that could shape the outlook for 2026",
    "summary": "Investing.com - A shift to an asset-based economy, rather than one focused on income, is accelerating, according to analysts at JPMorgan.",
    "url": "https://finnhub.io/api/news?id=2f089d55bf272f76cfbeb3247e3e81502b0e99ac2a94a609f13659459217d4e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767871244,
      "headline": "JPMorgan outlines ten strategic themes that could shape the outlook for 2026",
      "id": 138034976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Investing.com - A shift to an asset-based economy, rather than one focused on income, is accelerating, according to analysts at JPMorgan.",
      "url": "https://finnhub.io/api/news?id=2f089d55bf272f76cfbeb3247e3e81502b0e99ac2a94a609f13659459217d4e3"
    }
  },
  {
    "ts": null,
    "headline": "Last call: $300 Chase Freedom Unlimited bonus ending soon",
    "summary": "Depending on which other Chase credit cards you have, this welcome bonus can be worth much more in travel.",
    "url": "https://finnhub.io/api/news?id=f024cec0fada20503e8caf9342c7e2fc0f3f4237fc6dda47c2583dd76e76993e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767859202,
      "headline": "Last call: $300 Chase Freedom Unlimited bonus ending soon",
      "id": 138037819,
      "image": "https://image.cnbcfm.com/api/v1/image/108234142-1764554440479-gettyimages-2193120520-red22.jpeg?v=1767629796&w=1920&h=1080",
      "related": "JPM",
      "source": "CNBC",
      "summary": "Depending on which other Chase credit cards you have, this welcome bonus can be worth much more in travel.",
      "url": "https://finnhub.io/api/news?id=f024cec0fada20503e8caf9342c7e2fc0f3f4237fc6dda47c2583dd76e76993e"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Chase to take over Apple card from original issuer Goldman Sachs",
    "summary": "CNBC's Joe Kernen reports on the latest news.",
    "url": "https://finnhub.io/api/news?id=a34ce03177e6a5c40b3f0226b3e4052a41f14f5a7e63837d5d6a1d4f3a21795a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767855808,
      "headline": "JPMorgan Chase to take over Apple card from original issuer Goldman Sachs",
      "id": 138037756,
      "image": "https://image.cnbcfm.com/api/v1/image/108249828-17678734701767873468-43391878209-1080pnbcnews.jpg?v=1767873470&w=1920&h=1080",
      "related": "JPM",
      "source": "CNBC",
      "summary": "CNBC's Joe Kernen reports on the latest news.",
      "url": "https://finnhub.io/api/news?id=a34ce03177e6a5c40b3f0226b3e4052a41f14f5a7e63837d5d6a1d4f3a21795a"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Chase becomes the new issuer of the Apple Card",
    "summary": "Apple expects the transition to take 24 months",
    "url": "https://finnhub.io/api/news?id=10096b02432ae6f8e39badef4d26f986d4e7649f07bb97fe8da71554cf8f2e1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767853915,
      "headline": "JPMorgan Chase becomes the new issuer of the Apple Card",
      "id": 138032857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Apple expects the transition to take 24 months",
      "url": "https://finnhub.io/api/news?id=10096b02432ae6f8e39badef4d26f986d4e7649f07bb97fe8da71554cf8f2e1e"
    }
  },
  {
    "ts": null,
    "headline": "Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference",
    "summary": "LEIDEN, Netherlands, January 08, 2026--Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15.",
    "url": "https://finnhub.io/api/news?id=9fdeb4578e0a1d7e0550b91daf3034cadb995ad571e6c5104784899fee3d5c83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767852000,
      "headline": "Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference",
      "id": 138033008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "LEIDEN, Netherlands, January 08, 2026--Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15.",
      "url": "https://finnhub.io/api/news?id=9fdeb4578e0a1d7e0550b91daf3034cadb995ad571e6c5104784899fee3d5c83"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Banks End 2025 On A High Note",
    "summary": "US bank stocks outpaced the broader market in December 2025 for the second consecutive month.",
    "url": "https://finnhub.io/api/news?id=079d0362ded93ca58c35178f0df8edc08f5ec1636f6fa834a03d98702b189fb9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767849600,
      "headline": "U.S. Banks End 2025 On A High Note",
      "id": 138034400,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405678211/image_1405678211.jpg?io=getty-c-w1536",
      "related": "JPM",
      "source": "SeekingAlpha",
      "summary": "US bank stocks outpaced the broader market in December 2025 for the second consecutive month.",
      "url": "https://finnhub.io/api/news?id=079d0362ded93ca58c35178f0df8edc08f5ec1636f6fa834a03d98702b189fb9"
    }
  },
  {
    "ts": null,
    "headline": "Looking At The Narrative For Banco Santander Chile After Neutral Analyst Repricing",
    "summary": "The recent update on Banco Santander Chile centers on a slightly higher fair value estimate of CLP 68.59, up from CLP 66.16, paired with a small reduction in the discount rate to 12.29% from 12.36%. These shifts broadly track the latest analyst research, where price targets have been nudged higher while ratings sit at Neutral, reflecting a balance between valuation support and more tempered earnings expectations. Read on to learn how you can stay informed about future changes in this evolving...",
    "url": "https://finnhub.io/api/news?id=7bab0437ce15febf5e21d6fc454685e41d46a863e36c40f3cd729ef5ee0cdb28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767848907,
      "headline": "Looking At The Narrative For Banco Santander Chile After Neutral Analyst Repricing",
      "id": 138033009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The recent update on Banco Santander Chile centers on a slightly higher fair value estimate of CLP 68.59, up from CLP 66.16, paired with a small reduction in the discount rate to 12.29% from 12.36%. These shifts broadly track the latest analyst research, where price targets have been nudged higher while ratings sit at Neutral, reflecting a balance between valuation support and more tempered earnings expectations. Read on to learn how you can stay informed about future changes in this evolving...",
      "url": "https://finnhub.io/api/news?id=7bab0437ce15febf5e21d6fc454685e41d46a863e36c40f3cd729ef5ee0cdb28"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight",
    "summary": "In late 2025, TimesSquare Capital Management added Mirum Pharmaceuticals to its U.S. Small Cap Growth Strategy as the company expanded its flagship liver disease therapy Livmarli toward a third indication and reported very large year-over-year revenue growth in the third quarter. Separately, Mirum disclosed it would present at the J.P. Morgan Healthcare Conference in January 2026, a platform that can showcase its rare disease portfolio and pipeline to a broad institutional audience,...",
    "url": "https://finnhub.io/api/news?id=275158a0d5f8d827908e9035506981a0ac40c1790ced6ff3a7b290279873e25f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767848882,
      "headline": "How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight",
      "id": 138033010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "In late 2025, TimesSquare Capital Management added Mirum Pharmaceuticals to its U.S. Small Cap Growth Strategy as the company expanded its flagship liver disease therapy Livmarli toward a third indication and reported very large year-over-year revenue growth in the third quarter. Separately, Mirum disclosed it would present at the J.P. Morgan Healthcare Conference in January 2026, a platform that can showcase its rare disease portfolio and pipeline to a broad institutional audience,...",
      "url": "https://finnhub.io/api/news?id=275158a0d5f8d827908e9035506981a0ac40c1790ced6ff3a7b290279873e25f"
    }
  },
  {
    "ts": null,
    "headline": "CNBC's Inside India newsletter: Can new airlines cure all that ails India's aviation sector?",
    "summary": "Despite being one of the fastest growing aviation market which is controlled by just two airlines, there are no winners in this sector.",
    "url": "https://finnhub.io/api/news?id=c39dc0ea55084013b61112c3d3083e3ed206ec92d168cf79fada3b35d8c35930",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767846372,
      "headline": "CNBC's Inside India newsletter: Can new airlines cure all that ails India's aviation sector?",
      "id": 138037821,
      "image": "https://image.cnbcfm.com/api/v1/image/100802479-107788047.jpg?v=1532564676&w=1920&h=1080",
      "related": "JPM",
      "source": "CNBC",
      "summary": "Despite being one of the fastest growing aviation market which is controlled by just two airlines, there are no winners in this sector.",
      "url": "https://finnhub.io/api/news?id=c39dc0ea55084013b61112c3d3083e3ed206ec92d168cf79fada3b35d8c35930"
    }
  },
  {
    "ts": null,
    "headline": "Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2026, at 1:30 p.m. Pacific Time.",
    "url": "https://finnhub.io/api/news?id=89f35c977ae44d42c9a1e0041d8243219048b78cc0b083f8acfa0ab2574c0e80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767835140,
      "headline": "Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138033011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2026, at 1:30 p.m. Pacific Time.",
      "url": "https://finnhub.io/api/news?id=89f35c977ae44d42c9a1e0041d8243219048b78cc0b083f8acfa0ab2574c0e80"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan in Deal for Apple Credit Cards",
    "summary": "JPMorgan Chase has reached a deal to take over the Apple credit-card program from Goldman Sachs. The biggest bank in the country will become the new issuer of the tech-giant’s credit card, one of the largest co-branded programs with some $20 billion in balances, in a deal that has been negotiated for more than a year.",
    "url": "https://finnhub.io/api/news?id=e663e64145422adea5a156f775f0eea243c7d8753c7bf1f89c4505c691102d1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767830849,
      "headline": "JPMorgan in Deal for Apple Credit Cards",
      "id": 138032861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan Chase has reached a deal to take over the Apple credit-card program from Goldman Sachs. The biggest bank in the country will become the new issuer of the tech-giant’s credit card, one of the largest co-branded programs with some $20 billion in balances, in a deal that has been negotiated for more than a year.",
      "url": "https://finnhub.io/api/news?id=e663e64145422adea5a156f775f0eea243c7d8753c7bf1f89c4505c691102d1c"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Chase Reaches Deal to Take Over Apple Credit Card",
    "summary": "JPMorgan Chase  has reached a deal to take over the  Apple  credit-card program from  Goldman Sachs  further cementing JPMorgan’s status as a behemoth in the credit-card sector and marking the final chapter of Goldman’s failed experiment in consumer lending.  The biggest bank in the country will become the new issuer of the tech-giant’s credit card, one of the largest co-branded programs with some $20 billion in balances.  The sides, which had been negotiating for more than a year, announced the deal  Wednesday confirming an earlier report in The Wall Street Journal.",
    "url": "https://finnhub.io/api/news?id=1dbc4378a4fc40898d5201302890fbd4c77ba37de4f63fb4c898c0678811464a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767830580,
      "headline": "JPMorgan Chase Reaches Deal to Take Over Apple Credit Card",
      "id": 138032862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan Chase  has reached a deal to take over the  Apple  credit-card program from  Goldman Sachs  further cementing JPMorgan’s status as a behemoth in the credit-card sector and marking the final chapter of Goldman’s failed experiment in consumer lending.  The biggest bank in the country will become the new issuer of the tech-giant’s credit card, one of the largest co-branded programs with some $20 billion in balances.  The sides, which had been negotiating for more than a year, announced the deal  Wednesday confirming an earlier report in The Wall Street Journal.",
      "url": "https://finnhub.io/api/news?id=1dbc4378a4fc40898d5201302890fbd4c77ba37de4f63fb4c898c0678811464a"
    }
  }
]